Compare Abeona Therapeutics Inc (ABEO) vs Lucid Group Inc (LCID) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lucid Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Lucid Group Inc trades at $5.83 (market cap $2.34B). The key difference: Lucid Group Inc is far larger — about 6.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LCID | |
|---|---|---|
Market Cap | $373.32M | $2.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $31.30 |
52-Week Low | $4.17 | $4.70 |
Enterprise Value | $228.22M | $4.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Lucid Group (LCID) trades at $5.995, down 1.4% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 deliveries of 3,093 vehicles, missing expectations, alongside a leadership overhaul. Financially, LCID shows severe losses with a net income margin of -239.81% in 2025 and negative cash flow from operations of -$2.93B, though revenue grew to $1.35B.
The outlook remains challenging due to persistent losses and high cash burn, but the consensus price target of $11.75 suggests potential upside if execution improves. Key risks include ongoing class-action lawsuits, competitive pressures in the EV market, and reliance on Saudi funding. Investors should weigh the high-risk profile against long-term growth prospects in electric vehicles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
